The large intestinal mucosa contains immunological structures that may potentially serve as a site for induction of mucosal immunity against infections. Adenovirus (Ad), which is effective in gene transfer to epithelia, may be an ideal antigen delivery system for vaccination at the large intestinal mucosa. To investigate this potential, we immunized mice with recombinant replication-deficient Ad through a single intracolorectal (ICR) administration. Effective transfer of encoded genes was found in both the epithelial layer and lamina propria of the colorectal mucosa. Dendritic cells were able to transfer antigen to the draining lymph nodes, where antigen-specific CD8 + T cells were primed. Functional antigen-specific CD8 + T cells and IgA-specific antibodies were detected during the effector phase in the large intestine. Compared to other immunization routes (intranasal, subcutaneous), ICR immunization induced stronger colorectal immune responses and more potent protection against rectal challenge with pathogenic viruses. Further, this immunization strategy provided vaginal protection, more potent than that induced by vaccination in the nose or skin. Therefore, large intestine mucosal immunization using Ad represents an effective vaccination strategy against virus infection at both rectal and vaginal mucosal tissue sites.
INTRODUCTION
Many infections occur primarily through entry via mucosal surfaces. Sexually transmitted infections, such as human immunodeficiency virus or herpes simplex virus type 2 (HSV-2), are usually transmitted through genital mucosa, but can also occur through the large intestine via the rectal route. The large intestinal epithelium is made up of a monolayer of epithelial cells, which physically isolates lumenal microorganisms from the underlying lamina propria (LP), representing the first line of host defense. 1,2 However, pathogens can enter the mucosa by infecting intestinal epithelial cells (IECs) or through an abraded, lacerated epithelium during sexual contact. 2, 3 Along the lining of the gastrointestinal tract, the mucosal immune system is made up of secretory antibodies, especially IgA, that can prevent the cellular entry of pathogens 3 and T cells, especially CD8 + T cells, that can play major roles in eradicating intracellular pathogens and eventually control the infection that has occurred. 4,5 Thus, the generation of immunological resistance at the mucosal surface may effectively protect the host against pathogen invasion via the mucosal surface.
A number of studies have shown that owing to the existence of the common mucosal immune system, immunization at one mucosal site provides better mucosal immune responses at a distant mucosal site than equivalent immunization through a systemic route. 6 -9 Immunization at the nose can induce mucosal responses at distal mucosae such as the vaginal tract. 10 -14 However, some data also suggest that nasal immunization may not be as effective as needed at these genitourinary mucosal sites. 6,7,9,15 Indeed, priming of immune cells locally in the draining lymph node (LN) at a mucosal infection site is likely to provide strong local mucosal immunity. 8 Mucosal dendritic cells (DCs) beneath the epithelium were shown to acquire pathogenderived antigens and present them to mucosal lymphocytes in draining LNs and stimulate these cells to become effector cells specific for these antigens. 16 -18 From a practical and clinical perspective, mucosal immunization through the large intestine, for example through the use of a suppository, may be ideal for local priming of this tissue. Although there has been an increasing interest in exploring immunization at the large intestinal mucosa, this approach is hampered owing to the lack of an ARTICLES effective means for antigen delivery and potent immunological adjuvants that can be used. 19 Adenovirus (Ad) is a non-enveloped, double-stranded DNA virus. In vivo , gene transfer mediated by adenoviral vectors expressing heterologous antigen genes has proved to be one of the most successful ways to trigger or modulate immune responses. 20, 21 Moreover, administration of Ad vectors to mice through the colonic mucosa was able to transfer therapeutic levels of cytokine genes for the experimental treatment of colitis. 22 -24 On the basis of these previous observations, in this study we employed Ad vectors as vaccines to immunize mice at the large intestinal mucosa by intracolorectal (ICR) administration and demonstrated that antigen-specific immune responses, including both cellular and humoral responses, were induced with a single dose of the vaccine. We also developed a novel mouse model for virus challenge at the large intestine using a highly pathogenic virus strain, HSV-2, to test the efficacy of the vaccination strategy. Importantly, ICR immunization induced more potent protection against colorectal challenge of HSV-2 compared to immunization by other routes. It is intriguing that this immunization strategy also conferred better protection at the vaginal mucosa.
RESULTS

Gene transfer to the large intestine by Ads
We first administered adenoviral vectors expressing the -galactosidase ( -gal) gene (Ad -gal) by ICR delivery to evaluate gene transfer to the colorectal mucosa of mice. Cell-associated -gal expression was seen in the epithelium, extending from mid-colon to the anal end ( Figure 1a ) , and also beneath the epithelium, in the LP ( Figure 1b ). There were more gene expression clusters in the epithelium than in the LP ( Figure 1c ).
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(1) The number is averaged from longitudinal tissue sections of three different whole colorectum. ( d , e ) Luciferase (Luc) enzymatic activity was measured at 2 days or as indicated after ICR administration of AdLuc. Luc activity determined by an increase in relative light unit (RLU) compared to background is expressed as mean ± s.e.m. from three mice in each group. * P < 0.05, * * P < 0.01, * * * P < 0.001. Results are representative of at least two independent experiments. -gal, -galactosidase; PFU, plaque-forming unit.
ARTICLES
By using Ad expressing luciferase (AdLuc) for quantification of gene expression, we showed that genes were predominantly transferred and expressed in the colorectum, primarily in the distal half, and minimally in the cecum and ileum ( Figure 1d ). In the colorectum, gene expression was abundant from day 1 through day 3 ( Figure 1e ). Thus, a significant amount of antigen can be transferred to the colorectal mucosa for mucosal immunization.
Transport of gene to draining LNs by intestinal DCs
We investigated whether large intestinal DCs are involved in processing Ad-delivered genes and inducing antigen-specific immune responses. Forty-eight hours after ICR administration of Ad expressing green fluorescent protein (GFP) (AdGFP), GFP-expressing cells were detected both in the large intestinal LP and iliac LNs (ILNs), the draining LNs for the large intestine ( Figure 2a , upper ( Figure 2b ). When DCs that had been transfected in vitro with Ad expressing ovalbumin (AdOVA) were injected into the colorectal mucosa, cytotoxic T lymphocytes (CTLs) against the OVA CTL epitope SIINFEKL were detected in the ILN, as assessed at day 5 after administration ( Figure 2c ). Therefore, DCs can transport antigen from the large intestine to ILNs and effectively prime antigen-specific T cells.
Induction of large intestinal immune responses by Ad ICR immunization
Antigen-specific CD8 + T-effector cells are essential for eliminating virally infected cells 25, 26 and produce interferon-(IFN-) ( Figure 3a ) . At a later time, day 14, IFN--secreting cells in ILNs became undetectable, in contrast to IFN--secreting cells in the colorectum and spleen, which were increased. Thus, Ad vector immunization by ICR administration effectively induced cellular immune responses in the large intestine. We found that CD8 + T cells were the primary cells that produce IFN-by this immunization protocol ( Figure 3b ) and as tested in the secondary lymphoid organs, the cells exhibited cytotoxic activities ( Figure 3c ) that were primarily CD8 + T-cell-mediated ( Figure 3d ). As Ad vectors are effective in inducing antibody responses, 29 we next measured antigen-specific antibodies after AdOVA ICR. Significant levels of OVA-specific mucosal IgA antibodies were detected in the homogenates of colorectal tissue ( Table 1 ) . Also, serum OVA-specific IgG2a was present at levels greater than IgG1 ( Table 1 ) . Thus, Ad vector immunization by ICR administration can effectively induce both antigen-specific cellular and humoral immune responses at the large intestinal mucosa.
Vaccination at the large intestine against local virus challenge
We next addressed the relevant question as to whether Ad immunization via the large intestinal mucosa can provide effective protection against infection in the large intestine. We evaluated the effectiveness of this novel immunization strategy in comparison with nasal (intranasal, IN) or systemic (subcutaneous, SC) immunization. Doses for ICR and IN were determined on the basis of equivalent antigen expression levels in the corresponding local tissue as assessed using transfer of AdLuc. We found that 2 × 10 9 PFU (plaque-forming unit) of Ad given ICR Figure S5b online) . Thus, our results suggest that primary vaccination at the large intestinal mucosa represents a more effective way to achieve vaginal protection in addition to rectal protection against infectious viral challenge.
DISCUSSION
In addition to transmission through the genitourinary tract, rectal transmission is a major mode of infection adding to the development of widespread sexually transmitted infections, 33, 34 in apparent pandemic proportions for decades. Developing a vaccination strategy that can effectively control either route of infection has been challenging. The development of protective immunity against these infections requires an effective approach with a powerful antigen delivery system and an appropriate route for vaccination. Using a highly pathogenic HSV-2 lethal challenge model, we show here that primary immunization at the large intestinal mucosa with Ad expressing glycoprotein B induced almost complete protection against subsequent rectal challenge of HSV-2. Additionally, such immunization conferred efficient protection at the vaginal mucosa against HSV-2 challenge. We reasoned that using viral vectors as vaccines would be suitable for induction of antiviral infection immunity because these vectors target the same specific arms of the immune system as do viruses in nature. However, more importantly, priming at the large intestinal mucosa should be advantageous in protecting against sexually transmitted infections because the most effective protection is induced at the site of immunization and the neighboring vaginal mucosa. 
ARTICLES
We showed effective gene transfer to the epithelium and LP of the large intestine, where the transgene was highly expressed for 3 days. This should give resident DCs in the large intestine sufficient time to acquire expressed antigens. Adenoviral vectors have been shown to be capable of activating DCs and stimulating T cells to become cytotoxic effector cells and produce cytokines such as IFN-on antigen exposure. 28 We found that MHC II + CD11c + DCs were positive for Ad-expressed antigens in the LP. Although these cells accounted for only a small proportion of total antigen-expressing cells in the large intestinal mucosa, almost all antigen-expressing cells in the ILNs were DCs. It is likely that only DCs migrated from the mucosal tissue to the draining LNs for induction of antigen-specific immune responses. Alternatively, as effective gene transfer was also found in the epithelium of the colorectal mucosa, immunogenicity in our system could be due to IECs directly presenting antigen to effector cells. Mayer and Shlien 35 initially showed that IECs express MHC class II and can take up and present antigens to T cells. More recently, a polarized epithelial cell line transfected to express HLA-DR was shown to present soluble antigen to restricted CD4 T cells. 36 The contact of IECs with underlying immune cells in the LP may be facilitated owing to the presence of fenestrations or pores, 0.5 -5 µ m in diameter, in the basement membrane immediately below the intestinal epithelium, allowing immune cells to migrate between compartments and also IECs to project basal protrusions into the LP. 37, 38 Together, these studies raise important questions concerning how antigen is transferred to effector cells in the intestinal mucosa.
There were opposing changes over time in the frequencies of functional antigen-specific T cells found in different tissues, a decrease in the ILNs but an increase in both spleen and LP, and kinetic changes in CTL presence are mirrored by IFN-ELISPOT assessments. These discrepant kinetics might be due to the fact that antigen-specific CD8 + T cells emigrate from the ILNs after clonal expansion 39, 40 and ultimately return to the local mucosal tissues via the bloodstream. 18 Thus, ILNs might represent the major induction site for the large intestinal mucosa, where priming of antigen-specific CD8 + T cells occurs during days 4 -6 after immunization, and this immunization can induce antigen-specific T cells that are able to home to the site of immunization.
After Ad ICR immunization, we detected a significant production of antigen-specific colorectal IgA antibodies, in keeping with previous studies. 29, 41 It is worth noting that mice protected from lethal outcome by ICR immunization demonstrated virus replication and local inflammation after HSV challenge, indicating that mucosal cells were infected immediately post-challenge. As protection was completely abrogated in CD8 and IFNknockout mice, it appears that T-cell immunity plays an essential role in providing protection at the large intestinal mucosa and presumably at the vaginal mucosa as well, in addition to humoral immunity having an early role in immunological resistance. 42 We noticed that IVAG immunization with Ad did not generate adequate protective vaginal immunity. Our previous studies 43 showed protection against vaginal challenge after IVAG immunization, but with a 20-fold lower dose of HSV-2 at challenge; however, evaluation was not performed at higher doses as used here. Moreover, others have shown that the vaginal mucosa was not effective in antigen transfer and in inducing vaginal antibody responses. 44 -46 This may be due to the lack of inductive structures in the vaginal mucosa or difficulty with antigen penetration into the vaginal epithelium. However, our results showed that large intestine immunization provided effective vaginal protection against HSV-2. As ILNs drain both the rectum and female urogenital mucosae, 8 immunization at the large intestine also resulted in priming of T cells derived from vaginal mucosa through the lymphatic system. These primed cells may be eventually destined to home to vaginal mucosa. Thus, vaginal mucosa probably acts more as an effector site than as an inductive site, and large intestinal immunization with Ad is a promising strategy for vaginal protection against viral infection.
It was previously shown that immunization through the nose confers immunity and protection at the vaginal tissue against a low-dose herpes challenge. 14,47 However, we show here that mucosal immunization by the IN route is only marginally more effective than systemic immunization, when challenged with a high lethal dose of infectious HSV-2 virus, even though measurable immune responses can be detected. Even after using higher doses of AdgB for IN immunization, the animals showed no improvement in protection (data not shown). We reasoned that the use of a higher virus dose for lethal challenge in this study accounts for the differences seen from our earlier findings. In fact, we found that IN immunization, similar to SC, induced substantially lower ILN responses compared to ICR. This may be due to the sub-compartmentalized immunologic networks within the common mucosal immunologic system as suggested. 48 It is probable that entry of lymphocytes into the large intestine and vagina requires a specific homing mechanism that is restricted to those cells that are activated through specific mucosal sub-compartments. Therefore, the insufficient accumulation of activated local mucosal lymphocytes plus local mucosal antibodies after IN or SC immunization could result in the poor effector function seen at either colorectal or vaginal mucosae.
ICR vaccination may be considered as " regional " or " local " immunization for both the large intestine and vaginal tracts, as they are geographically neighboring within the same sub-compartmentalized immune network in the mouse and a similar genitorectal lymphatic system is found in humans. 49 In previous studies mainly using cholera toxin for vaccines, limited effects at the vaginal mucosa were shown not only in mice 13,50 -52 and monkeys 12,51 but also in humans. 10, 11, 53 In addition, effects at other mucosal sites such as lung, nose, and saliva were similarly minimal. 52 These studies indicate that mucosal immunization with cholera toxin and protein vaccines provides immunity primarily at the site of immunization. Thus, both animal and human studies have encountered difficulties in generating vaginal immunity through vaccination by the rectal route . However, our data shown here demonstrate in principle that ICR vaccination with Ad-expressed antigen gene leads ARTICLES to beneficial local protection in the mouse. We reasoned that the effective vaginal protection induced by rectal immunization was due to the use of Ad as a powerful system of antigen delivery and immune activation, compared to some others. Ads have no significant side effects if administered at appropriate low doses, 54, 55 and their mucosal epithelial tropism maximizes immunological consequences at the intestinal mucosa. 56 -59 Comparison studies by Shiver et al. 60 showed that although Ad and poxvirus were almost equally effective when used for boosting, priming with poxvirus was ineffective, as opposed to Ad, regardless of boosting agents. Interestingly, Ad efficiently promotes human DC maturation and production of inflammatory cytokines, 61, 62 whereas poxvirus may inhibit DC maturation and antigen presentation for T-cell priming. 63 -65 The differences between two vectors in DC activation and antigen presentation may contribute to the difference in the results of our studies and the monkey trials as well as recently published clinical outcomes. 66, 67 Similarly, in spite of its strong immune stimulation, cholera toxin as a vaccine adjuvant has been shown to be a potent inhibitor of both mitogen-and antigen-induced T-cell activation 68, 69 and mediate apoptosis of CTL. 70, 71 Whether this activity was responsible for the ineffectiveness of vaginal immunity induced through gut immunization remains to be determined. Therefore, as suggested earlier, choosing the right venue and a suitable and potent antigen delivery and immune activation system for vaccination is extremely important. 53 As the nature of the vaccine will most likely influence the outcome, our strategy of using Ad to deliver antigen genes to the colorectal tissue may provide benefits that are unique in overcoming apparent limitations of the mucosal immune system and provide protection to the vaginal mucosa, suggesting that testing this concept in humans may be worthwhile.
Although the details of this experimental immunization with Ad at the colorectal mucosa remain to be determined for direct translation to humans, using suppositories to administer vaccines would seem to be a logical progression from our studies. Potentially, applying ICR vaccination has many advantages in humans over other vaccination routes: (1) it is less invasive and highly applicable using suppository form; (2) it avoids menstrual cycles, which affect vaginal delivery of vaccines; (3) no vital organs such as the respiratory system and brain are jeopardized, as sometimes happens following IN immunization; (4) it bypasses the small intestine where tolerance may be induced after oral delivery 72, 73 ; and (5) if proven to be effective in males, ICR vaccination using Ad or similar viral delivery systems may benefit the other half of the population in the world.
In conclusion, our results indicate that large intestine immunization with Ad represents an effective vaccination strategy against viral infections transmitted through the rectal tissue, and at least in the mouse, provides functional protection at the vaginal mucosa. Using an animal model of genital HSV-2 infection, which is relevant to human sexually transmitted infections, we provide an innovative vaccination strategy for humans to defend against HSV exposure and could also be potentially used to immunize against human immunodeficiency virus. EL-4, CV-1, and Vero cell lines ( American Type Culture Collection (ATCC), Manassas, VA, USA) were cultured in complete RMPI medium. Bone marrow cells were cultured in the presence of 10 ng ml − 1 of granulocyte macrophage colonystimulating factor and 10 ng ml − 1 of interleukin-4 for generation of DCs as described previously. 75 At day 6, cells were infected with Ad 1 day before administration. VV-OVA was recovered from tissues 6 days after challenge by homogenization. 9 HSV-2 was recovered from the vaginal tract 76 or the rectal lumen by swabbing. Plaque-forming assays were performed with CV-1 or Vero cells for 48 h, followed by counterstaining with 5 % w / v crystal violet. Virus presence was expressed as total PFUs (log 10 PFUs) / organ or fluid sample.
METHODS
Animals
Replication-deficient Ad expressing chicken OVA was constructed as described below. Total RNA was isolated from fresh oviduct tissue of Gallus gallus (chicken), and the first strand was synthesized with Superscript RT and oligo dT primers (Invitrogen Corp, Carlsbad, CA). PCR was performed with Vent Polymerase (Invitrogen Corp) using primers (forward: 5 Ј -GTTCACCATGGGCTCCATCGGCGCAGCAAGCAT GG-3 Ј ; and reverse: 5 Ј -CTACAGTGCTCTGGGTCTTGTTGGAAGG GAC-3 Ј ). Sma I (T4 ligase, New England Biolabs, Beverly, MA) was used to digest pDC104. Purified OVA PCR fragment was cloned into a vector as pDC104ova6. The pDC104ova6 and pBHG10-CRE plasmids were co-transfected into 293 cells, as described previously, 77 and the product was confirmed with Southern and western blot, respectively. The OVA 257 -264 epitope SIINFEKL for H2-K b was confirmed by sequence analysis. Immunogenicity of AdOVA was demonstrated by the ability to induce significant primary CTL responses in the popliteal LN following footpad injection. AdOVA were propagated in 293 cells and purified by cesium chloride gradient centrifugation. 77 Recombinant AdLuc, Ad -gal, AdGFP (huAd5), and AdBHG contain firefly luciferase, Escherichia coli -gal, GFP, and no heterologous gene, respectively. 78 All virus stocks were aliquoted and stored at − 70 ° C before use.
Administration route and animal models. Mice were anesthetized during the following procedures. For ICR administration, virus in 100 µ l phosphate-buffered saline was pipetted into the colorectum shortly after 50 % ethanol pretreatment. 79 The anal opening was sealed for 4 -5 h with Dermabond (Ethicon, Somerville, NJ) to prevent leakage. For IVAG administration, mice were given subcutaneously 2 mg Depo-Provera (medroxyprogesterone acetate; Pharmacia & Upjohn, Kalamazoo, MI) 5 days before immunization to thin the lining of the vaginal wall. 76, 80 Virus (in 10 µ l aliquots) was pipetted into the lumen followed by Dermabond at the vaginal opening. For intermucosal administration, DCs were injected into the rectal mucosal from the anus using a 0.3 ml insulin syringe with 30G × 3 / 8 Љ needle (Terumo, Somerset, NJ). Two animal models were used: an OVA model using AdOVA for immunization and recombinant VV-OVA for challenge, 9 and an HSV model using AdgB for immunization and HSV-2 for challenge. After HSV challenge, perianal inflammation and hind limb paralysis were clinically scored to evaluate infection status ( Table 2 ) .
Cell isolation and tissue homogenates. Colorectum was removed and fragmented into a few pieces and stirred for 30 min at 37 ° C with Ca 2 + -and Mg 2 + -free Hanks ' balanced salt solution containing 10 % fetal bovine serum, 15 m M HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 5 m M EDTA, 0.014 % w / v dithiothreitol, and 100 µ g ml − 1 gentamycin to isolate epithelial cells and intraepithelial lymphocytes, which were then discarded by filtering. The remaining fragments ARTICLES were further cut into smaller pieces and incubated with complete RPMI 1640 medium containing 250 U ml − 1 collagenase VIII (Sigma Chemical, Somerville, NJ). LPLs were purified from liberated cells by a 30 % / 75 % gradient of Percoll (Sigma Chemical). To prepare tissue homogenates, tissues were removed and homogenized in phosphate-buffered saline with a homogenizer (POLYTRON, Kinematica, Cincinnati, OH).
-gal staining and luciferase assay. Fresh colorectal tissue was placed in tissue fixative (2 % formaldehyde, 0.05 % glutaradehyde, 1.6 sodium cacodylate, and 0.025 % calcium chloride) for 30 min on ice and microwaved for 5 -8 s at ~ 45 ° C and immediately put back on ice. The samples were overlain with 1 mg ml − 1 X-gal (5-bromo-4-chloro-3-indolyl -D-galactoside, Sigma Chemical) at ~ 37 ° C overnight in staining buffer. Samples were washed with phosphate-buffered saline, fixed in 10 % formalin for 48 h, paraffin-embedded, and cut into 4 -5 µ m-sections and counterstained with eosin and nuclear fast red. Cell-based blue staining clusters were enumerated under the microscope. Luciferase activity was measured using the Luciferase Assay System Kit (Promega, Madison, WI) according to the manufacturer ' s instructions.
Flow cytometry and 51 Cr release assay. Antibodies were purchased from BD Biosciences Pharmingen (Mississauga, ON). Splenocytes were stimulated for 4 -6 h at 37 ° C with 2 µ M SIINFEKL (Sigma Genosys, Woodlands, TX) in the presence of brefeldin A. Following surface staining, cells were fixed and permeabilized before intracellular cytokine staining. Samples were analyzed with a FACScan (Becton Dickinson, Sunnyvale, CA) and WinMDI 2.8 software (The Scripps Research Institute, La Jolla, CA). Dead cells were excluded using forward and side scatter measurements. For Cr release assay, EL-4 cells pulsed with 1 µ M SIINFEKL were labeled with sodium chromate as target cells and incubated for 4 h at 37 ° C with CD8 + effectors. Supernatants were harvested and measured for radioactivity. 75 To block CD8-mediated CTLs, 10 µ l of anti-CD8 blocking antibody (53-6.72, ATCC) or isoytpe control IgG2a antibody was added to T cells 30 min before the assay.
ELISPOT and ELISA. Mouse IFN-ELISpot kit (R & D Systems, Minneapolis, MN) was used according to the manufacturer ' s directions. In short, freshly isolated cells were seeded in an IFN-antibody-precoated 96-well filter plate and cultured with 1 µ M SIINFEKL at 37 ° C for 24 h. Captured IFN-was assayed by using biotinylated IFN-detection antibodies in conjunction with Strep-AP / BCIP-NBT. Spot numbers twofold higher than the background were considered as positive. For enzyme-linked immunosorbent assay, colorectal homogenates or sera were serially diluted and incubated in OVA protein-precoated plates for 2 h. The plates were then incubated with alkaline phosphatase-conjugated anti-mouse IgA, IgG1, or IgG2a detection antibodies for 2 h, and color was developed by incubating p -nitrophenyl phosphate for 30 min in darkness before reading optical density. Antibody titers were derived from the inverse dilution at which the sample yielded an optical density twice that of the background of control specimens from non-immunized mice.
Statistical analysis.
Comparisons between groups were analyzed by Student ' s t -test. Comparisons among means of more than two groups were determined by one-way analysis of variance post hoc with Bonferroni correction. Analyses were performed with SPSS for Windows (SPSS, Chicago, IL). P -values < 0.05 were considered statistically significant. 
